Chronix's Liquid Biopsy Test Shows Promise In Predicting Therapeutic Response To Chemo
Chronix Biomedical's blood-based liquid biopsy test showed promise in predicting therapeutic response to chemotherapy in a blinded proof-of-concept study presented at the American Association for Cancer Research (AACR) annual meeting in New Orleans, Louisiana (April 16-20).
You may also be interested in...
Chronix Biomedical continues to demonstrate the potential of its blood-based cancer test across a growing range of indications – this time, its ability to help doctors assess how well patients are responding to immunotherapy, at an earlier stage than current diagnostic imaging methods.
Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.